Literature DB >> 28863833

Allergic diseases: From bench to clinic - Contribution of the discovery of interleukin-5.

Tsutomu Yanagibashi1, Mitsuo Satoh2, Yoshinori Nagai3, Masamichi Koike2, Kiyoshi Takatsu4.   

Abstract

T helper 2 cells produce a number of cytokines including inteleukin (IL)-5, IL-4 and IL-13. Group 2 innate lymphoid cells (ILC2s) also produce IL-5 under sterile conditions. IL-5 is interdigitating homodimeric glycoprotein and a member of the four α helical bundle motifs conserved among hematopoietic cytokines. IL-5 exerts its effects on target cells via IL-5 receptor (IL-5R), composed of an IL-5R α and βc subunit. The membrane proximal proline-rich motif of the cytoplasmic domain of both IL-5R α and βc subunits is essential for IL-5 signal transduction. Although IL-5 was initially identified by its ability to support the growth and terminal differentiation of mouse B cells into antibody-secreting cells, recombinant IL-5 exerts pleiotropic activities on various target cells. For example, IL-5 is now recognized as the major maturation and differentiation factor for eosinophils in mice and humans. Overexpression of IL-5 in mouse significantly increases eosinophil numbers and antibody levels in vivo, while mice lacking a functional gene for IL-5 or IL-5R display developmental and functional impairments in B cell and eosinophil lineages. In mice, the role of the IL-5/IL-5R system in the production and secretion of Immunoglobulin (Ig) M and IgA in mucosal tissues has been reported. Although eosinophils protect against invading pathogens including virus, bacteria and helminthes, they are also involved in the pathogenesis of various diseases, such as food allergy, asthma, and inflammatory bowel diseases. The recent expansion in our understanding in the context of IL-5 and IL-5-producing ILC2s in eosinophil activation and the pathogenesis of eosinophil-dependent inflammatory diseases has led to advances in therapeutic options. A new therapy currently under invetigarion in clinical trials uses humanized monoclonal antibodies against IL-5 or the IL-5R. In this review, we summarize our current understanding of the functions of IL-5 and its receptor, the innate regulation of IL-5-producing cells, and therapeutic potential of anti-IL-5 and anti-eosinophil (IL-5R) antibodies.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Allergy; Benralizumab; Eosinophil; ILC2; Mepolizumab/Reslizumab; Severe asthma; Th2

Mesh:

Substances:

Year:  2017        PMID: 28863833     DOI: 10.1016/j.cyto.2016.11.011

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  19 in total

Review 1.  The use of biologics for immune modulation in allergic disease.

Authors:  Willem van de Veen; Mübeccel Akdis
Journal:  J Clin Invest       Date:  2019-03-18       Impact factor: 14.808

Review 2.  Human eosinophils and mast cells: Birds of a feather flock together.

Authors:  Piper A Robida; Pier Giorgio Puzzovio; Hadas Pahima; Francesca Levi-Schaffer; Bruce S Bochner
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

Review 3.  Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.

Authors:  Loïc Raffray; Loïc Guillevin
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

4.  Establishment and characterization of a new human first trimester Trophoblast cell line, AL07.

Authors:  Hong Liu; Liling Wang; Yan Wang; Qian Zhu; Paulomi Aldo; Jiahui Ding; Gil Mor; Aihua Liao
Journal:  Placenta       Date:  2020-08-21       Impact factor: 3.481

Review 5.  New treatment directions in food allergy.

Authors:  Vanitha Sampath; Sayantani B Sindher; Wenming Zhang; Kari C Nadeau
Journal:  Ann Allergy Asthma Immunol       Date:  2018-03       Impact factor: 6.347

Review 6.  Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?

Authors:  Andrea Matucci; Alessandra Vultaggio; Enrico Maggi; Ismail Kasujee
Journal:  Respir Res       Date:  2018-06-08

7.  Promising Effects of Benralizumab on Chronic Eosinophilic Pneumonia.

Authors:  Kohsuke Isomoto; Tomohisa Baba; Akimasa Sekine; Naoto Aiko; Takashi Ogura
Journal:  Intern Med       Date:  2020-02-01       Impact factor: 1.271

Review 8.  Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.

Authors:  Corrado Pelaia; Alessandro Vatrella; Andrea Bruni; Rosa Terracciano; Girolamo Pelaia
Journal:  Drug Des Devel Ther       Date:  2018-03-21       Impact factor: 4.162

Review 9.  Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma.

Authors:  Corrado Pelaia; Cecilia Calabrese; Alessandro Vatrella; Maria Teresa Busceti; Eugenio Garofalo; Nicola Lombardo; Rosa Terracciano; Girolamo Pelaia
Journal:  Biomed Res Int       Date:  2018-05-10       Impact factor: 3.411

10.  A low abundance of Bifidobacterium but not Lactobacillius in the feces of Chinese children with wheezing diseases.

Authors:  Zhang Liwen; Wan Yu; Ma Liang; Xu Kaihong; Cheng Baojin
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.